Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vera Therapeutics, Inc. (Nasdaq: VERA) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a late clinical-stage biotechnology company focused on serious immunological diseases, Vera Therapeutics uses SEC filings to report clinical milestones, financing transactions, governance changes, and other material events that can be important for investors analyzing VERA stock.
Current reports on Form 8-K feature prominently in Vera Therapeutics’ filing history. For example, the company has filed 8-Ks describing entry into a Sales Agreement with TD Securities (USA) LLC for potential at-the-market offerings of Class A common stock, the pricing of underwritten public offerings of Class A common stock, and the termination of a prior sales agreement. Other 8-Ks report clinical and regulatory updates, such as ORIGIN Phase 3 trial data for atacicept in immunoglobulin A nephropathy (IgAN), including reductions in proteinuria and safety outcomes, as well as the submission of a Biologics License Application and subsequent communications around FDA review.
Filings also cover corporate governance and compensation. Vera Therapeutics has reported the appointment of new directors, including committee assignments and equity compensation under its non-employee director compensation policy, and changes in executive roles such as the departure of its Chief Legal Officer. Additional disclosures describe inducement equity awards granted under the company’s 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Alongside 8-Ks, investors can access registration statements and prospectus supplements referenced in the filings, which relate to public offerings and shelf registration on Form S-3. These documents outline the terms under which Vera Therapeutics may issue Class A common stock to fund its development programs, including atacicept, VT-109, and MAU868.
On Stock Titan, Vera Therapeutics’ SEC filings are updated in near real time from EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as clinical trial disclosures, financing capacity, director and officer changes, and at-the-market sales arrangements. Users can quickly scan which filings relate to clinical data, capital raising, or governance, and then drill down into the full text when more detail is needed.
For those tracking insider and equity-related activity, the filings page complements Forms 4 and other ownership reports by surfacing information on option grants, RSUs, and inducement awards described in 8-Ks. Together, these materials provide a detailed view of how Vera Therapeutics structures incentives and finances its late-stage development efforts in immunology and nephrology.
T. Rowe Price Associates, Inc. reports beneficial ownership of 5,461,988 shares of Vera Therapeutics common stock, representing 7.7% of the class as of December 31, 2025. It has sole voting power over 5,376,319 shares and sole dispositive power over 5,461,976 shares, with no shared voting or dispositive power.
The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young received new equity awards. On February 4, 2026, he was granted 10,000 shares of Class A Common Stock in the form of restricted stock units at $0 per share, bringing his directly held stock to 67,839 shares.
He was also granted stock options for 20,000 shares of Class A Common Stock at an exercise price of $42.74 per share, all held directly. The RSUs vest in four equal annual installments each February 20 from 2027 through 2030, while the options vest over 48 months starting March 4, 2026, subject to his continued service.
Vera Therapeutics President and CEO Fordyce Marshall reported new equity awards tied to continued service. On February 4, 2026, he received 68,800 RSUs of Class A common stock at no cost under the 2021 Equity Incentive Plan, vesting in four equal annual installments each February 20 from 2027 through 2030.
He was also granted a stock option for 137,500 shares of Class A common stock at an exercise price of $42.74 per share, with 1/48 vesting on March 4, 2026 and the remainder vesting monthly thereafter. Following these awards, Marshall reports 274,088 Class A shares held directly, plus indirect holdings of 122,949 shares through a GRAT and 99,081 shares through The Fordyce Revocable Trust.
Vera Therapeutics’ chief financial officer Sean Grant received new equity awards in the form of restricted stock units and stock options. On February 4, 2026, he was granted 25,000 RSUsstock option for 50,000 shares at an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, subject to continued service. The option vests over four years, beginning March 4, 2026, with monthly vesting thereafter, also conditioned on continued service. Following this grant, Grant directly holds 119,130 Class A shares plus 50,000 options, and 5,000 additional shares are held indirectly through a trust.
Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported new equity awards. On February 4, 2026, he received 20,000 shares of Class A Common Stock for $0, representing restricted stock units granted under Vera’s 2021 Equity Incentive Plan. After this award, he directly owned 65,800 Class A shares.
He was also granted a stock option for 40,000 shares of Class A Common Stock at an exercise price of $42.74 per share. One forty-eighth of the option vests on March 4, 2026, with the remainder vesting in equal monthly installments, while the RSUs vest in four equal annual installments each February 20 from 2027 through 2030, all subject to continued service.
Vera Therapeutics Chief Regulatory Officer receives new equity awards. William D. Turner was granted 25,000 restricted stock units (RSUs) of Class A Common Stock and a stock option covering 50,000 shares. The option has a $42.74 exercise price and was granted for no cash consideration.
One-fourth of the RSUs vest on each of February 20, 2027, 2028, 2029 and 2030, if he remains in service. The option vests in 48 equal monthly installments, starting March 4, 2026, also subject to continued service. After these grants, he directly holds 47,500 Class A shares and 50,000 options.
Vera Therapeutics Chief Operating Officer receives new equity awards. On February 4, 2026, David Lee Johnson was granted 20,000 restricted stock units of Class A Common Stock at a price of $0 under Vera’s 2021 Equity Incentive Plan and 40,000 stock options with an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, assuming continued service. The stock options begin vesting on March 4, 2026, with 1/48th of the grant vesting monthly, also conditioned on continued service. Following the RSU grant, he beneficially owns 48,306 Class A shares directly.
Vera Therapeutics Chief Medical Officer granted RSUs and stock options
Vera Therapeutics’ Chief Medical Officer, Robert Brenner, reported equity awards dated February 4, 2026. He received 25,000 shares of Class A common stock in the form of restricted stock units, granted at $0 cost. These RSUs vest in four equal annual installments on February 20, 2027, 2028, 2029 and 2030, if he remains in continuous service.
He also received a stock option for 50,000 shares of Class A common stock at an exercise price of $42.74 per share, expiring on February 3, 2036. One forty‑eighth of the option vests on March 4, 2026, with the remainder vesting monthly thereafter, subject to continued service. After these transactions, Brenner directly beneficially owns 53,098 shares of Class A common stock.
FMR LLC2,885,853 shares, representing 4.1% of the class.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. FMR LLC has sole voting power over 2,878,610 shares and sole dispositive power over 2,885,853 shares, while Abigail P. Johnson reports sole dispositive power over the same 2,885,853 shares.
Vera Therapeutics’ Chief Commercial Officer, Skelton Laurence Matthew, has filed an initial ownership report showing equity-based incentives in the company. He holds 30,000 and 15,800 shares of Class A Common Stock underlying restricted stock units that vest in tranches from November 2026 through February 2029, subject to continued service.
He also holds stock options for 60,000 shares at an exercise price of